Fujitsu 2012 Annual Report Download - page 69

Priority 1
Cancer is well on the way to becoming the leading cause of
death globally, due in part to aging societies and modern life-
styles. With cancer incidence expected to increase by 75% by
2030, the need is urgent to develop effective treatments. How-
ever, experimental drugs only have a 0.01% chance of making it
to market. Raising development success rates is a pressing issue.
In collaboration with the University of Tokyo’s Research Center for
Advanced Science and Technology and Sweden’s Stockholm
University, Fujitsu is working to leverage IT-enabled drug
The Kingdom of Morocco is a constitutional monarchy located in
northwest Africa, with a population of roughly 32 million people.
With the country’s mobile phone market continuing to grow
rapidly, Méditel, the second-
largest domestic mobile
telecommunications provider,
needed to quickly manage
increasing communications
traffic from the provision of
increasingly sophisticated
services to ever more users.
Amid rising food demand and more severe water shortages due
to climate change, roughly 13% of the world’s population does
not have access to safe drinking water, and nearly half of house-
holds lack running water.
Meanwhile, Japan’s water and sewerage infrastructure is
aging, with nationwide upgrades called for in 2015. This is prob-
lematic for many local governments that manage water and
sewer operations due, in part, to a lack of financial resources and
experienced engineers.
To address these issues, top-tier water treatment player
Metawater Co., Ltd. teamed up with Fujitsu to build a water
business cloud (WBC). This IT infrastructure enables remote
monitoring of facilities spanning a wide geographic area.
discovery simulation technologies to reduce the conventional
level of repetition for animal tests and clinical trials, helping to
markedly shorten new drug development timelines and cut costs.
Fujitsu will keep striving to contribute to the development
and improvement of effective pharmaceuticals for an array of
intractable diseases like cancer by performing high-precision
simulations utilizing the lightning-fast computational speed of
a supercomputer.
Fujitsu joined forces with partner company PTI (Portugal Telecom
Inovação, SA) to offer an IT platform with high processing capac-
ity, enabling Méditel to roll out new services for its 10 million
users and handle feature expansion.
The Fujitsu Group’s IT platforms will support globalization in
Morocco and other emerging economies around the world.
The WBC makes it possible for local governments and other
water and sewer business operators to use shared IT infrastruc-
ture. This framework is projected to reduce lifecycle costs, includ-
ing system installation and running
costs, by at least 30% compared with
conventional water and sewerage wide-
area surveillance.
Fujitsu will utilize cloud computing
technologies to support sustainable
water and sewerage operations into
the future.
New drug development support via highly accurate simulation to predict binding activity
Search for Medicinal Combinations
Discover drug effects without actual creation
Heuristics and
experiments
To date
Simulations
Going forward
Compound (drug)
Protein
Key Examples from Fiscal 2011
Collaborative Research with Stockholm University
Using Supercomputers to Accelerate International IT-enabled Drug Discovery
Fujitsu Group IT Platform to Handle Sharp Rise in Communications Traffic from Sophisticated Mobile Phone
Services in Morocco
Provision of a New Cloud Service to Support Water and Sewer Operations
Moroccans using mobile phone services
WBC remote support services
Providing Opportunities and Security through ICT
067
FUJITSU LIMITED ANNUAL REPORT 2012
Responsibility